The ace inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice

Pharmacological Research

Volumn 46, Issue 6, 2002, Pages 505-510

  Sawada, Tokihiko ^a   Ishii, Yasuo ^a   Tojimbara, Tamotsu ^a   Nakajima, Ichiro ^a   Fuchinoue, Shohei ^a   Teraoka, Satoshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme; EPS; Peritoneal dialysis; Quinapril

Indexed keywords

ALCOHOL; CHLORHEXIDINE GLUCONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL; SODIUM CHLORIDE; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RETROPERITONEAL FIBROSIS; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; PATHOLOGY; SCLEROSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; ISOQUINOLINES; MICE; MICE, INBRED C57BL; RETROPERITONEAL FIBROSIS; SCLEROSIS; TETRAHYDROISOQUINOLINES;

EID: 0036453666     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043661802002281     Document Type: Article

References (22)

1. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Geis WP, Hano JE. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140: 120-3.
2. Denis J, Paineau J, Potel G, Fontenaille C, Guenel J. Continuous ambulatory peritoneal dialysis. Ann Intern Med 1980; 93: 508.
3. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
4. Holmes CJ. CAPD-associated peritonitis: An immunological perspective on causes and intervention. Contrib Nephrol 1990; 86: 73-90.
5. Fern RJ, Yesko CM, Thornhill BA, Kin HS, Smithies O, Chevalier RL. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999; 103: 39-46.
6. Border WA, Noble NA. Effect of maximal reduction of angiotensin in renal fibrosis: Bad news-good news from a pediatric mouse. Am J Kidney Dis 2000; 35: 773-6.
7. Nakajima T, Yamada T, Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 19: 102-7.
8. Naftilan AJ, Pratt MJ, Owens GK. Induction of platelet-derived growth factor A chain and c-myc gene expression by Angiotensin II in cultured rat muscle cells. J Clin Invest 1989; 83: 1419-24.
9. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-61.
10. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16: 1262-6.
11. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, Margolin SB. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 147: 287-91.
12. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1970; 20: 1637-48.
13. Weber KT. Angiotensin II and connective tissue: Homeostasis and reciprocal regulation. Regul Pept 1999; 82: 1-17.
14. Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, Oritz A, Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995; 48: 1778-91.
15. Wolf G, Muller E, Stahl RAK, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cell is mediated by endogenous transforming growth factor β. J Clin Invest 1993; 92: 1366-72.
16. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 2000; 36: 894-902.
17. Border WA, Nobel NA. Transforming growth factor β in tissue fi-brosis. New Engl J Med 1994; 331: 1286-92.
18. Border WA, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 1993; 8: 1-9.
19. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesan-gial cells. J Clin Invest 1944; 93: 2431-7.
20. Johnston CI, Fabris B, Yamada H, Mendelsohn FAO, Cubela R, Sivell D, Jackson B. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989; 7(Suppl 5): S11-6.
21. Kinoshita A, Urata H, Bumpus M, Husain A. Measurement of angiotensin II converting enzyme inhibition in the heart. Circ Res 1993; 73: 51-60.
22. Ichikawa I, Harris RC. Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int 1991; 40: 583-96.